Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity.
D000818:Animals; D000956:Antigens, Viral / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology; D005260:Female; D005822:Genetic Vectors / Q000008:administration & dosage; D006801:Humans; D007271:Injections, Intradermal; D008198:Lymph Nodes / Q000276:immunology; D008213:Lymphocyte Activation; D051379:Mice; D009369:Neoplasms / Q000517:prevention & control*; D009856:Oncogene Proteins, Viral / Q000235:genetics / Q000276:immunology*; D050725:Papillomavirus E7 Proteins; D010957:Plasmids / Q000008:administration & dosage; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology; D015678:Viral Structural Proteins / Q000235:genetics*
D000956:Antigens, Viral; D019496:Cancer Vaccines; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D019444:Vaccines, DNA; D015678:Viral Structural Proteins; C073413:herpes simplex virus type 1 protein VP22; C059731:oncogene protein E7, Human papillomavirus type 16